Table 2.
Cancer type | miRNA | Number of samples | Prognostic correlation | Ref |
---|---|---|---|---|
colorectal cancer | MIR221 | TCGA data | Overexpression predicts short OS rates. | [31] |
hepatocellular carcinoma | MIR135A | 103 pairs of cancerous and non-cancerous samples | Overexpression predicts short OS rates. | [32] |
non-small cell lung carcinoma | MIR150 | 54 cancerous and 30 non-cancerous tissues | Overexpression predicts short OS rates. | [33] |
Glioma | MIR449A | 72 pairs of cancerous and non-cancerous samples | Overexpression predicts short OS rates. | [34] |
uterine sarcoma |
MIR152 and MIR24 |
101 cancerous and 54 non-cancerous samples | Overexpression predicts better OS rates. | [96] |
osteosarcoma | MIR129 | 18 pairs of cancerous and non-cancerous samples | Overexpression predicts better OS rates. | [118] |
ALL, AML, APL | MIR23A | 25 primary ALL, 27 AML, 15 APL samples | Overexpression predicts better OS rates. | [129] |
hepatocellular carcinoma | MIR30A | 9 pairs of cancerous and non-cancerous samples | Overexpression predicts better OS rates. | [132] |